Navigation Links
TopoTarget Successfully Buys Back Full Control of Belinostat
Date:4/22/2008

Target shares issued through a directed issue of shares and a commercial milestone payment of a total of USD 6 million (approximately DKK 28.3 million), which is defined as 10% of the first USD 60 million (approximately DKK 283.5 million) of belinostat sales or partnership revenues.

Belinostat is currently being tested in 18 clinical trials (10 sponsored by the NCI) to treat different types of cancer. Belinostat is safe and well-tolerated also when combined with chemotherapy, and has the unique flexibility of being administered both intravenously and orally in capsule form. This differentiates belinostat from its competitors. In 2007, the product was included in Windhover Information's top ten of the most interesting cancer products for partnering.

"TopoTarget will now push forward the development of belinostat to benefit cancer patients and will focus on bringing the drug to the market as soon as possible. Today's deal represents a great opportunity for TopoTarget and its shareholders by gaining sole ownership of belinostat. We can now pursue an initial registration in PTCL using our in house proven clinical and regulatory team and focus on pursuing a partnership with a large pharma which has the development and commercialisation muscle to exploit belinostat's blockbuster potential," said Peter Buhl Jensen, CEO of TopoTarget.

TopoTarget's belinostat strategy TopoTarget will now focus its resources on the development of belinostat, and the company has initiated a reorganisation to reflect this focus. In the second half of this year TopoTarget expects to launch the first registration trial in PTCL, a disease where no standard treatment is approved. TopoTarget is also pursuing a fast track status and an orphan drug status for this indication. With clinical trials commencing in the second half of 2008, TopoTarget believes a market approval could be obtained in 2010.

TopoTarget also expects to pursue a development programme in ovarian cancer
'/>"/>

SOURCE TopoTarget A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
2. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Life on Mars pregnancy test successfully launched
7. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Citrate appears to control buckyball clumping but environmental concerns remain
10. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
11. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... WA and VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... financial results will be released on Monday, November 10, ... and live webcast at 4:30,p.m. EDT that afternoon. Management ... update on the business and product pipeline., To ...
... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ... results for the three and nine-month periods ... Decision, Oncolytics made a decision in ... randomized trial using the combination of REOLYSIN(R) ...
... N.J., Nov. 4 Cambrex,Corporation (NYSE: CBM ) reports third ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased ... third quarter 2007. -- Adjusted EBITDA for the quarter was ... $9.7 million last year. -- Debt, net of cash was ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Release Third Quarter Financial Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/25/2014)... Neuregulin 1 (NRG1) is a pleiotropic factor characterized ... alternative splicing of exons that confer to the ... role for both the myelination occurring during development ... the peripheral nerve: axon degeneration, axon regrowth, remyelination ... Western Australia have discovered that the soluble NRG1 ...
(Date:7/25/2014)... development of diffusion tensor tractography (DTT), which is ... and estimation for three motor tracts, such as ... corticoreticular pathway became possible. The corticospinal tract is ... motor function in the human brain. Several studies ... by transtentorial herniation. In addition, some studies have ...
(Date:7/25/2014)... at the Stowers Institute for Medical Research ... receptors, and found pheromones crucial to triggering the mating ... receptors helps a male mouse detect pheromones that indicate ... receptors lets him know if the female mouse is ... are critical to trigger mating. Stowers, researchers believe mice ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3
... and Yuh Nung Jan, PhD, of the Howard Hughes ... will jointly receive the 2012 Neuroscience Prize of The ... contributions to the field of molecular neurobiology, particularly their ... activity and on how brain cells diversify and specialize ...
... Calif.) You pick up your cell phone and dial ... At. A. Time. Because you haven,t actually typed the number ... sequence of distinct movements. After dialing the number a ... a series of three successive bursts of movement: the area ...
... use plants as ,green phones, for communication with other ... same plants insects are also able to leave ,voicemail, ... via their effects on soil fungi. Researchers from the ... discovered this unique messaging service in the ragwort plant. ...
Cached Biology News:UCSF pair win Gruber Foundation Neuroscience prize 2UCSF pair win Gruber Foundation Neuroscience prize 3UCSF pair win Gruber Foundation Neuroscience prize 4Study by UC Santa Barbara psychologists reveals how brain performs 'motor chunking' tasks 2Study by UC Santa Barbara psychologists reveals how brain performs 'motor chunking' tasks 3Voicemail discovered in nature 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: